Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
* * $LLY Video Chart 06-11-15 * *
Link to Video - click here to watch the technical chart video
LLY buys North American rights to Erbitux from BMY: #msg-112837296.
LLY issues 2015 non-GAAP EPS guidance: #msg-109697754.
quick ques,what does everybody think lilly will be trading at between now and 90 days from now price wise and where the company is headed?....
biotech_researcher Tuesday, 10/28/14 05:20:17 PM
Quote:SNY/NVO/LLY—More on the competitive landscape in diabetes:
http://www.google.com/url?sa=t&rct=j&q=&esrc=s&frm=1&source=web&cd=1&ved=0CCQQFjAA&url=http%3A%2F%2Fblogs.wsj.com%2Fpharmalot%2F2014%2F10%2F28%2Fsanofi-diabetes-outlook-signals-an-undisciplined-price-war-may-erupt%2F&ei=-cBaVO7iJMyyoQT30YGoDQ&usg=AFQjCNHQD878MVZWf9c-44r6rnplMW862w&bvm=bv.78677474,d.cGU&cad=rjt
"In fact, the U.S. payer market is consolidating. Glaxo, as Moneybeat notes, estimates that the 10 largest commercial plans now control 86% of the marketplace, creating more visibility on contracting strategies and pricing. “I think you have a general shift in power toward the purchaser,” Glaxo chief executive Andrew Witty told analysts last week. Glaxo, for instance, is struggling to successfully launch its new Aroro respiratory treatment."
What is new in Bio Tech and where do the Greatest Opportunities reside:
DewDiligence, Sorry for the delay in answering your question. With a name like DewDiligence, one would think you would know that "FS" means Forward Split.
What does FS mean?
"Looking at the universe of stocks we cover at Dividend Channel, on 11/13/13, xxxxxxx and Eli Lilly & Co. (NYSE: LLY) will all trade ex-dividend for their respective upcoming dividends. xxxxxxxx and Eli Lilly & Co. will pay its quarterly dividend of $0.49 on 12/10/13."
LLY
Eli Lilly Bulls: How Will 2014 Treat You?
Oct 29 2013, 10:08 | about: LLY, includes: BMY, MRK, RHHBY BOOK
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. Fusion Research is a team of equity analysts. This article was written by Satya Prakash, one of our research analysts. We did not receive compensation for this article (other than from Seeking Alpha), and we have no business relationship with any company whose stock is mentioned in this article. (More...)
In our previous article on Eli Lilly (LLY), we discussed the six-month patent extension for "Cymbalta", the blockbuster drug used for treatment of major depressive disorder, or MDD. Cymbalta generated revenue of $5 billion last year and its patent will be expire in December 2013. Evista, another drug of Eli Lilly that is used for preventing and treating osteoporosis in women after menopause, will be losing its patent in March 2014. These two drugs contribute nearly 26% of Lilly's revenue and their patent expiry may hamper its 2014 sales and earnings.
However, we expect Lilly's strong presence in oncology, endocrinology, and cardiovascular markets with drugs including Alimta, Evista, Humalog, Erbitux, and Cialis will drive its earnings in the future. The positive result for its trial Phase drugs will help it expedite the drug approval to further increase its revenue and offset the revenue losses from the patent expiration of Cymbalta and Evista.
On October 23, 2013, the company declared strong third quarter results, mainly driven by high revenue and its ongoing cost cutting plans.
Highlights of third quarter
Lilly reported year-over-year revenue growth of 6% to $5.77 billion.
Gross margin increased 8% to $4.57 billion with net income of $1.2 billion.
EPS non-GAAP increased 41% year over year to $1.11 per share.
Lilly submitted application for "Dulaglutide", a type 2 diabetes drug, for regulatory review in both the U.S. and Europe.
In Phase III trial, as a first-line treatment, its cancer drug, "Necitumumab", met the primary endpoint in treating stage IV metastatic cancer and increasing the overall survival in combination with gemcitabine and cisplatin compared to chemotherapy alone.
The company submitted for approval of "Ramucirumab" as a single-agent for the treatment of gastric cancer in Europe.
Ramucirumab in combination paclitaxel met both the safety and efficacy profile in its Phase III trial.
Opportunity in Gastric Cancer
On September 26, 2013, Eli Lilly declared the results for RAINBOW and ROSE Phase III trials for "ramucirumab." The RAINBOW trial is the global Phase III study of ramucirumab in combination with Bristol-Myers Squibb's (BMY) "paclitaxel", a mitotic inhibitor used in chemotherapy, to treat patients suffering with advance gastric cancer. Ramucirumab was able to meet the primary endpoint in improving the overall survival and secondary endpoint in improving progression-free survival. Under this RAINBOW trial, Ramucirumab with paclitaxel demonstrated the superior efficacy and safety in comparison to the placebo.
Gastric cancer is responsible for worldwide deaths of more than 800,000 patients per year. It is the third leading cause of cancer-related death globally in men and the fifth in women and the second most cause of cancer-related death. It is most prevalent in the countries outside the U.S. and Europe. Gastric cancer cells can travel through the bloodstream and may affect organs like lungs, liver, and bones. We expect the positive Phase III result of ramucirumab provides a great opportunity for the company in the gastric cancer market.
After looking at the superior RAINBOW Phase III trial results, the company is planning to submit an application for ramucirumab in combination with paclitaxel to regulatory authorities for its approval to treat patients with advance gastric cancer. As these cancer cells affect the liver and lungs, it is also testing ramucirumab's efficacy in trial to treat cancer of these organs.
Ramucirumab's superior results in REGARD trial
On October 3, 2013, Eli Lilly announced the Phase III REGARD trial of ramucirumab as a single agent in treating patients with advance gastric cancer compared to placebo. In this trial, around 238 patients were treated with the dose of 8mg/kg of ramucirumab and 117 patients received the placebo intravenously once every two weeks. After the eight week of dosing, patients with the single-agent ramucirumab were able to achieve the overall survival of 5.2 months compared to 3.8 months with the placebo, and it reduced the risk of death by around 22%. The patients treated with ramucirumab achieved the progression-free survival of 2.1 months compared to 1.3 months with placebo.
Currently, there are no drugs specifically approved in the U.S. and Europe for advanced gastric cancer patients. The company submitted ramucirumab as a single-agent for regulatory approval in the U.S. and Europe. Based on its superior results compared to placebo, we expect the company may receive the regulatory approval easily, and ramucirumab will provide a higher growth opportunity for the company.
Growth with other cancer drug
In June 2012, Eli Lilly and Bristol-Myers, with their partner Merck (MRK), received FDA approval for "Erbitux", a colorectal cancer drug, as the first-line treatment in KRAS mutation. Merck has the right to develop and market Erbitux outside North America, while Bristol-Myers and Eli Lilly will market it in North America. Additionally, Eli Lilly, as the owner of Erbitux, is eligible to receive royalties on its sales. Erbitux has generated revenue of $333 million in the second quarter of 2013 for Eli Lilly.
The company has initiated trials for evaluating the efficacy of Erbitux and demonstrated the superior results of Erbitux compared to Roche Holding's (OTC:RHHBY) "Avastin". In a trial it observed that 342 colon cancer patients dosed with Erbitux showed superior efficacy; it has reported the average survival rate of 33.1 months compared to 25.6 months for those treated with Avastin. Erbitux is only approved for treatment of patients suffering with tumors containing the non-mutated version of gene, KRAS, a protein. This protein is responsible for developing many cancers and accounts for 60% of colorectal cancer cases. Eli Lilly is planning to receive regulatory approval in Europe for this drug. It is expected to provide a higher growth opportunity for the company. Erbitux sales are expected to peak at $1.25 billion in 2014 and may slip to $1.1 billion by 2018, as the other drug manufacturers will be free to launch biosimilars in Europe by 2015. This will also help Eli Lilly generate higher revenue and royalties on Erbitux sales through its partners.
On other side, Roche, which is known as the world biggest cancer drug manufacturer, recently posted its third-quarter results. It has reported the year-over-year revenue growth of 6% to $38.2 billion for the first nine months of 2013. This growth was mainly driven by the strong performance of its cancer drugs, which include Avastin, Herceptin, MabThera/Rituxan, Perjeta, and Kadcyla.
The increased uptake of Perjeta and Kadcyla, which have demonstrated superior efficacy in enhancing the survival rates of the women suffering with aggressive breast cancer, and Avastin and Herceptin, its other cancer drugs used for the treatment of advance form of cancer, helped Roche post revenue of $12.67 billion for its third quarter of 2013.
Avastin was approved for treating ovarian cancer in Europe, colorectal cancer in the U.S., and its first approval for newly diagnosed glioblastoma in Japan increased its revenue 13% year over year. With this strong growth, we expect its leading cancer drugs will continue to drive its revenue in the future, and it will be able to maintain its leadership in the cancer drugs market.
Conclusion
We are very optimistic about Eli Lilly's drug pipeline and expect its new drugs to perform significantly in the next few years. The positive response from ramucirumab in treating gastric cancer patients may make it another blockbuster drug for the company, if it reports positive results in treating other forms of cancers also. In its recent guidance, Eli Lilly believes it will generate revenue in the range of $22.6 billion to $23.4 billion in fiscal year 2013. It also expects the EPS growth of 18%-20% in the range of $4.33-$4.38 in 2013. Eli Lilly's stock price witnessed the high of $51 on its result day and generated the return of nearly 4% for its investors.
LLY Chart
(Click to enlarge)
LLY data by YCharts
Further, Eli Lilly, despite patent expiration of its main antidepressant drug, Cymbalta, reaffirmed the revenue guidance of at least $20 billion, net income of $3 billion, and $4 billion in operating cash flow next year. The company also expects to return $5 billion to investors in the form of share buyback and dividends. Recently, it declared the fourth quarter dividend of $0.49 per share payable on December 10, 2013, with the record date of November 15, 2013. Its share buyback plan shows the company's confidence in its future growth and its new drug launches.
We expect the company's initiatives coupled with its strong drug pipeline and the positive response for its new drugs, ramucirumab, Necitumumab, and Dulaglutide, will help the company maintain its future earnings, likely achieve its guidance quite comfortably, and drive the investors' confidence.
______________________________________________
seekingalpha.com/article/1781552-eli-lilly-bulls-how-will-2014-treat-you?source=email_rt_article_readmore
LLY
Eli Lilly: Cymbalta Patent Expiry Quantified
Oct 28 2013, 12:48
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)
On December 11th, Eli Lilly (LLY) will lose U.S. patent protection of its antidepressant blockbuster Cymbalta (duloxetine) and the product's U.S. sales are expected to decline significantly. Cymbalta currently accounts for 24% of Lilly's global revenue.
During Q3-2013 earning call, Lilly's management volunteered an estimate of how much sales Cymbalta might lose in the last quarter of this year. We've done the calculations and we tend to agree with Lilly's management that during 2013 the effect of Cymbalta's patent expiry on the company's bottom line will be minimal.
(click to enlarge)
Cymbalta's U.S. sales this year have been $1.1 billion, $1.2 billion and $1.1 billion for the first three quarters, respectively. Lilly anticipates that U.S. Cymbalta sales in Q4 will be closer to $500 million, compared to a street consensus of nearly $800 million for the quarter.
Cymbalta, which generated a total of $29 billion in sales since it was first launched by Lilly in 2004, is expected to generate $5 billion in global sales this year.
Cymbalta is the global leader in the antidepressant therapeutic class with close to 80% of sales realized in the U.S. Several manufacturers have already received approvals to market generic versions of the product and are expected to launch their generics immediately following the loss of patent exclusivity.
Current retail price for Cymbalta can reach over $250 for a month's supply while a generic equivalent would cost less than $20, and there is no major difference in treatment outcome between the two products.
Lilly's management expects minimal wholesaler repurchases after the patent expires on December 11th as well as minimal wholesaler purchases in the three weeks leading up to the patent expiration as wholesalers work down their existing inventories to post-patent expirations levels.
Lilly seems to be prepared to successfully navigate the financial challenge posed by Cymbalta's patent expiration. The company is planning to continue investing in R&D, recapitalize its asset base and return substantial cash to shareholders.
Lilly's board of directors authorized a new $5 billion share repurchase program, which the company intends to complete over a multi-year period, and the company is planning to keep dividend payments at their current levels for the foreseeable future.
During 2013, Lilly completed the regulatory submission of several potential new drugs. The company submitted dulaglutide, designed to be injected weekly for Type II diabetes, in both, the U.S. and Europe and, along with Boehringer Ingelheim, submitted empagliflozin for Type II diabetes.
Lilly also aims to expand its cancer arsenal beyond its Alimta lung-cancer treatment. The company has applied to market a potential gastric-cancer treatment, ramucirumab, which could be launched next year and which analysts say has solid sales potential. It also expects to seek marketing approval before the end of 2014 for a potential lung-cancer drug, necitumumab.
(click to enlarge)
Lilly's Q3 revenue increased 6% driven by growth in key products, including Cymbalta, Alimta, Cialis, Tradjenta, Humalog, Strattera, Humulin and Animal Health. However, its Q3 net income declined 9%. The per share earning decline was slightly less at 6%, reflecting the benefit of its share repurchases late last year and early this year.
Lilly survived generic pressures before. After it lost patent protection for its popular antidepressant Prozac in 2001, a new wave of blockbusters including antidepressant Cymbalta and the erectile-dysfunction pill Cialis helped it recover.
Lilly has restocked its pipeline, in part with modest-size acquisitions and licensing deals, and avoided the type of megamergers pursued by Pfizer (PFE) and Merck (MRK). The pipeline looks robust and could help the company get through Cymbalta's patent loss.
Lilly's share price seems unchanged from its level at the beginning of the year, however it is currently down by 13% from its peak for the year, which was achieved in April. At a P/E of 12 and the prospects of $5 billion in share buybacks, Lilly's shares looks like good value for the time being.
__________________________________________________________
http://seekingalpha.com/article/1778932-eli-lilly-cymbalta-patent-expiry-quantified?source=email_rt_article_readmore
LLY
Earnings Beat from Eli Lilly Again - Analyst Blog
By Zacks.com, October 23, 2013, 12:08:05 PM EDT
Eli Lilly & Company ( LLY ) reported third quarter 2013 adjusted earnings per share of $1.11, well above the Zacks Consensus Estimate of $1.05 and 41% above the year-ago earnings of 79 cents. Year-over-year growth was attributable to the strong performance of several key products, cost control, a lower tax rate as well as a lower share count.
Third quarter revenues increased 6% to $5.77 billion, marginally above the Zacks Consensus Estimate of $5.76 billion. Revenues increased despite the impact of the Zyprexa patent expiry due to the strong performance of key products.
Reported earnings (including special items) declined 6% to $1.11 per share in the third quarter of 2013.
Quarterly Details
Third quarter revenues increased 6% reflecting price increases (5%) and higher volume (3%) that were partially offset by unfavorable currency fluctuation (2%). The higher volume was mainly due to the strong performance of several products like Humalog, Alimta, Trajenta and Forteo and the Animal Health segment. This was partially offset by the loss of exclusivity for Zyprexa, which is facing competition from several generic players as well as volume declines for Cymbalta.
U.S. revenues grew 11% to $3.3 billion mainly due to price increases, especially for Cymbalta. Ex- U.S. revenues remained flat at $2.5 billion mainly due to the unfavorable impact of the depreciation of the Japanese yen.
During the third quarter, Zyprexa recorded a 26% decline in revenues, which came in at $278.7 million. U.S. revenues fell 51% due to lower prices. International revenues decreased 20%, mainly due to the loss of market exclusivity in major markets apart from Japan. Zyprexa sales in Japan were affected by the weakening yen.
Products which performed well in the third quarter included Alimta (up 7% to $690.5 million), Humalog (up 7% to $616 million), Cialis (up 9% to $526.7 million), Forteo (up 6% to $306.7 million) and Strattera (19% growth to $173.2 million) among others.
Cymbalta sales increased 11% to $1.4 billion. However, growth was driven mainly by price increases. With the Cymbalta patent expiry coming up (Dec 11), inventory levels were down both at the wholesale and retail channels. The company expects U.S. sales to drop to about $500 million in the fourth quarter.
Eli Lilly's Animal Health segment contributed $530.3 million (up 11%) to revenues. Sales benefited from the withdrawal of Merck's ( MRK ) food animal product from the U.S. market.
Effient revenues increased 14% to $124.9 million. While U.S. revenues grew 15% to $92.7 million, due to higher prices, ex- U.S. revenues increased 10% to $32.2 million driven by higher volume and favorable currency movement.
Expenses
Eli Lilly's adjusted operating expenses declined 2% to $3 billion. Research and development (R&D) expenses increased 3% to $1.4 billion. Marketing, selling and administrative expenses declined 6% to $1.7 billion reflecting the company's cost control efforts. The company has cut down its sales and marketing activities in the U.S. for Cymbalta and Evista, due to impending generic competition.
EPS Guidance Narrowed
Eli Lilly narrowed its 2013 earnings guidance to $4.10 to $4.15 per share (old guidance: $4.05 - $4.15 per share). Revenue guidance remained unchanged at $22.6 billion - $23.4 billion. The Zacks Consensus Estimate for earnings and revenues is currently $4.12 per share and $22.9 billion, respectively.
Eli Lilly continues to expect marketing, selling and administrative expenses of $7.0 - $7.2 billion and R&D expenses of $5.3 - $5.5 billion.
Eli Lilly will start buying back shares under its new $5 billion share repurchase program shortly.
Our Take
Eli Lilly's third quarter results were once again better-than-expected with products like Cialis, Humalog, Alimta, Forteo and the animal health segment managing to offset the negative impact of the genericization of Zyprexa.
Eli Lilly expects revenues to remain flat or increase by about 3.5% in 2013 despite the expected loss of U.S. exclusivity for Cymbalta later this year.
While revenues will be impacted by the loss of Cymbalta exclusivity and the loss of the 15% royalty on exenatide sales, products like Humalog, Humulin, Cialis, Strattera, Forteo, Alimta, Cymbalta (outside the U.S.), Effient, Tradjenta and Axiron, and the animal health segment should contribute to sales. Emerging markets, especially China, should also drive sales. However, revenue growth in Japan could be adversely affected by the weak yen.
Eli Lilly is also working on controlling costs. Earlier this year, Eli Lilly had announced a restructuring initiative to help lessen the impact of the upcoming loss of patent exclusivity for Cymbalta and Evista, changing consumer needs and the change in the U.S. healthcare environment.
Eli Lilly currently carries a Zacks Rank #3 (Hold).
Read more: http://www.nasdaq.com/article/earnings-beat-from-eli-lilly-again-analyst-blog-cm290621#ixzz2ijlrsl00
_______________________________________________________
LLY
FDA Approves Addition to CIALIS® (tadalafil) Product Label
Study Data Shows Cialis 5 mg Initiated with Finasteride Provides Significantly Greater Improvements in Urinary Symptoms of Benign Prostatic Hyperplasia than Placebo with Finasteride
INDIANAPOLIS, Oct. 25, 2013 /PRNewswire/ --
Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved a product label addition for CIALIS to include data from a 26-week study that showed CIALIS 5 mg for once daily use started in combination with finasteride significantly improved the signs and symptoms of benign prostatic hyperplasia (BPH) as early as 4 weeks, compared to placebo with finasteride, in men with BPH and an enlarged prostate. The combination of CIALIS and finasteride initiated for BPH therapy is recommended for up to 26 weeks because the incremental benefit of CIALIS decreases from 4 weeks until 26 weeks, and the incremental benefit of CIALIS beyond 26 weeks is unknown.
CIALIS is approved by the FDA to treat erectile dysfunction (ED), the signs and symptoms of BPH, and both ED and the signs and symptoms of BPH (ED+BPH). Finasteride is a type II 5 alpha-reductase inhibitor (5-ARI) approved by the FDA for the treatment of BPH in men with an enlarged prostate.
"Urinary symptom improvement with 5-ARI therapy can take 6 to 12 months," said Claus Roehrborn, MD, chairman, Department of Urology, The University of Texas Southwestern Medical Center. "These data demonstrate that the combination of CIALIS 5 mg for once daily use with finasteride leads to symptom improvement as early as four weeks in men with BPH and an enlarged prostate. This means that CIALIS 5 mg for once daily use can be an effective option for early symptom relief when started in combination with finasteride."
The primary endpoint of the study - changes in total International Prostate Symptom Score (IPSS) at 12 weeks - demonstrated that symptom improvement in patients starting BPH treatment with CIALIS 5 mg for once daily use and finasteride was greater than those starting with placebo and finasteride (-5.2 vs. -3.8; P = .001). Key secondary endpoints demonstrated that improvements in IPSS occurred at the first scheduled observation at week 4 (-4.0 vs. -2.3; P< .001) and continued through week 26.
It is important to note that CIALIS is not to be taken with medicines called "nitrates" such as isosorbide dinitrate or isosorbide mononitrate which are often prescribed for chest pain; or with recreational drugs called "poppers" like amyl or butyl nitrite, as the combination may cause an unsafe drop in blood pressure; or if allergic to CIALIS or ADCIRCA® (tadalafil), or any of its ingredients. Anyone who experiences any symptoms of an allergic reaction, such as rash, hives, swelling of the lips, tongue or throat, or difficulty breathing or swallowing, should call a healthcare provider or get help right away.
In a subgroup of patients with BPH who were also sexually active and had ED at baseline, CIALIS initiated with finasteride significantly improved erectile function, as measured by the International Index of Erectile Dysfunction–Erectile Function Domain, compared to placebo with finasteride. These results were evident at 4 weeks (3.7 vs. -1.1; P< .001), 12 weeks (4.7 vs. 0.6; P< .001) and 26 weeks (4.7 vs. 0.0; P< .001).
About the Study
The randomized, double-blind, placebo-controlled, 26-week trial assessed the efficacy and safety of CIALIS 5 mg for once daily use or placebo co-administered with finasteride 5 mg in 696 men aged 45 years and older (mean age 64) with an IPSS of at least 13, a urine flow rate (Qmax) of 4 millimeters per second (mL/sec) to 15 mL/sec and a prostate volume at least 30 mL. The study was conducted at 70 sites in 13 countries.[1]
The primary measure was the IPSS, a questionnaire evaluating lower urinary tract symptoms occurring during the preceding month where lower scores indicate less severe symptoms. The pre-specified secondary measure was the International Index of Erectile Function-Erectile Function Domain (IIEF-EF), a questionnaire evaluating erectile function where higher scores indicate better erectile function.
Results from the Phase 3b study – Study H6D-CR-LVIW – have been accepted for publication in The Journal of Urology and are available now online at http://dx.doi.org/10.1016/j.juro.2013.09.059.
About BPH and ED
Benign prostatic hyperplasia (BPH) is a condition where the prostate enlarges, which can cause urinary symptoms like needing to go urgently and frequently.
ED is a condition where the penis does not fill with enough blood to harden and expand when a man is sexually excited, or when he cannot keep an erection.
BPH and ED are conditions that may occur in the same patient. Several studies have shown that many men with ED also experience the symptoms of BPH.[2],[3],[4]
About CIALIS
CIALIS is indicated for the treatment of men with erectile dysfunction (ED), men with the signs and symptoms of benign prostatic hyperplasia (BPH), and men with both ED and the signs and symptoms of BPH. CIALIS is not for women or children. If CIALIS is used with finasteride to initiate BPH treatment, such use is recommended for up to 26 weeks.
Important Safety Information for CIALIS® (tadalafil) tablets
What Is The Most Important Information I Should Know About CIALIS?
Do not take CIALIS if you:
take medicines called "nitrates" such as isosorbide dinitrate or isosorbide mononitrate which are often prescribed for chest pain as the combination may cause an unsafe drop in blood pressure
use recreational drugs called "poppers" like amyl nitrite and butyl nitrite
are allergic to CIALIS or Adcirca® (tadalafil), or any of its ingredients. Call your healthcare provider or get help right away if you experience any symptoms of an allergic reaction, such as rash, hives, swelling of the lips, tongue or throat, or difficulty breathing or swallowing
After taking a single tablet, some of the active ingredient of CIALIS remains in your body for more than 2 days. The active ingredient can remain longer if you have problems with your kidneys or liver, or you are taking certain other medications.
Stop sexual activity and get medical help right away if you get symptoms such as chest pain, dizziness, or nausea during sex. Sexual activity can put an extra strain on your heart, especially if your heart is already weak from a heart attack or heart disease.
What Should I Tell My Healthcare Provider Before Taking CIALIS?
CIALIS is not right for everyone. Only your healthcare provider and you can decide if CIALIS is right for you. Ask your healthcare provider if your heart is healthy enough for you to have sexual activity. You should not take CIALIS if your healthcare provider has told you not to have sexual activity because of your health problems. Before taking CIALIS, tell your healthcare provider about all your medical problems, particularly if you have or ever had:
heart problems such as chest pain (angina), heart failure, irregular heartbeats, or have had a heart attack
high or low blood pressure or have high blood pressure that is not controlled
stroke
liver or kidney problems or require dialysis
retinitis pigmentosa, a rare genetic (runs in families) eye disease
severe vision loss, including a condition called NAION
stomach ulcers or a bleeding problem
a deformed penis shape or Peyronie's disease
an erection that lasted more than 4 hours
blood cell problems such as sickle cell anemia, multiple myeloma, or leukemia
Can Other Medicines Affect CIALIS?
Tell your healthcare provider about all the medicines you take especially if you take:
medicines called "nitrates" which are often prescribed for chest pain
alpha-blockers often prescribed for prostate problems
blood pressure medications
medicines for HIV or some types of oral antifungal medications
some types of antibiotics such as clarithromycin, telithromycin, erythromycin (several brand names exist, please contact your healthcare provider to determine if you are taking this medicine)
other medicines or treatments for erectile dysfunction (ED)
CIALIS is also marketed as Adcirca for the treatment of pulmonary arterial hypertension. Do not take both CIALIS and Adcirca. Do not take sildenafil citrate (Revatio®)* with CIALIS.
What Should I Avoid While Taking CIALIS?
Do not use other ED medicines or ED treatments while taking CIALIS.
Do not drink too much alcohol when taking CIALIS (for example, 5 glasses of wine or 5 shots of whiskey). Drinking too much alcohol can increase your chances of getting a headache or getting dizzy, increasing your heart rate, or lowering your blood pressure.
What Are The Possible Side Effects Of CIALIS?
The most common side effects with CIALIS are: headache, indigestion, back pain, muscle aches, flushing, and stuffy or runny nose. These side effects usually go away after a few hours. Men who get back pain and muscle aches usually get it 12 to 24 hours after taking CIALIS. Back pain and muscle aches usually go away within 2 days. Call your healthcare provider if you get any side effect that bothers you or one that does not go away.
Uncommon but serious side effects include:
An erection that won't go away: If you get an erection lasting more than 4 hours, seek immediate medical help to avoid long-term injury.
In rare instances, men taking prescription ED tablets, including CIALIS, reported a sudden decrease or loss of vision or hearing (sometimes with ringing in the ears and dizziness). It's not possible to determine if these events are related directly to the ED tablets or to other factors. If you have a sudden decrease or loss of vision or hearing, stop taking any ED tablet, including CIALIS and call a healthcare provider right away.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
CIALIS does not:
cure ED
increase a man's sexual desire
protect a man or his partner from sexually transmitted diseases, including HIV
serve as a male form of birth control
CIALIS is available by prescription only. For additional information, talk to your doctor and see full Patient Information at http://pi.lilly.com/us/cialis-ppi.pdf and Prescribing Information at http://pi.lilly.com/us/cialis-pi.pdf, or visit www.cialis.com for more information.
* The brand listed is a trademark of its respective owner and is not a trademark of Eli Lilly and Company. The maker of this brand is not affiliated with and does not endorse Eli Lilly and Company or its products.
TD Con-F ISI 03FEB2012
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.
This press release contains forward-looking statements about the use of Cialis for the treatment of BPH and reflects Lilly's current beliefs. However, as with any pharmaceutical product under development, there are substantial risks and uncertainties in the process of development, commercialization, and regulatory review. There is no guarantee that the product will receive additional regulatory approvals. There is also no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
P-LLY
TD87005
[1] Casabe, A., Roehrborn, C.G., Da Pozzo, L.F., Zepeda, S., Henderson, R.J., Sorsaburu, S., Henneges, C., Wong, D.G., Viktrup, L. Efficacy and safety of the co-administration of tadalafil once daily with finasteride for 6 months: a randomized, double-blind, placebo-controlled study in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. The Journal of Urology. 2013; doi:10.1016/j.juro.2013.09.059.
[2] Rosen R, Altwein J, Boyle P, Roger SK, Lukacs B, Meuleman E, et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol. 2003;44(6):637-649.
[3] Brookes ST, Link CL, Donovan JL, and McKinlay JB. Relationship between lower urinary tract symptoms and erectile dysfunction: results from the Boston Area community Health Survey. J Urol 2008;179:250-255.
[4] Gacci M, et al. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. In press. Eur Urol 2011; doi:10.1016/j.eururo.2011.06.037.
Refer to: Kelly Hoffman, 317-631-6400 (office), 317-459-7826 (mobile),
kelly.hoffman@borshoff.biz
Morry Smulevitz, 317-651-5567 (office), 317-457-3294 (mobile),
smulevitzmb@lilly.com
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
RELATED LINKS
http://www.cialis.com
_____________________________________________________
http://www.prnewswire.com/news-releases/fda-approves-addition-to-cialis-tadalafil-product-label-229234431.html
LLY
Board of Directors authorized a new $5 billion share repurchase program
In the last eight months, Eli Lilly has completed eight U.S., European and Japanese regulatory submission for four potential new medicines; Empagliflozinm, insulin glargine product in collaboration with Boehringer Ingelheim, dulaglutide and ramucirumab.
The company had a number of clinical data readouts, including positive readouts for SQUIRE, a Phase 3 study investigating necitumumab as first-line treatment for squamous non-small cell lung cancer and for RAINBOW, a Phase 3 study of ramucirumab as combination therapy in patients with advanced gastric cancer. In both studies, Eli Lilly saw increased overall survival.
Also for ramucirumab, the Phase 3 RA study in first-line breast cancer failed to meet its primary endpoint of increased progression free survival.
http://stks.co/qY6W
Lilly diabetes drugs, price hikes fuel 6% sales boost
By Carly Helfand Comment | Forward | Twitter | Facebook | LinkedIn
Last quarter, Eli Lilly managed to up its earnings through raising prices and slashing its workforce. This quarter, the Indianapolis pharma giant ($LLY) built on that strategy while adding some higher revenues from diabetes products into the mix. But at least some analysts are skeptical whether Lilly can hang its hat on its diabetes franchise going forward.
Wednesday, Lilly reported third-quarter earnings that fell 9% to $1.11 a share. But that profit topped analyst estimates, and the company can thank a worldwide sales increase of 6% for at least some of that. Diabetes drugs drove the jump, with Humulin sales leaping 22% in the U.S. and Humalog revenues increasing by 6% at home and 8% abroad.
Lilly also managed to reduce costs again for the quarter, shedding 4% of its operating expenses. Crippled by the patent cliff last year as best-seller Zyprexa fell to generic competition, the company has worked to chip away at losses by cutting down on spending. And with new top-seller Cymbalta about to follow suit, Lilly has once again found itself staring down the barrel of a gun. July company-wide salary freezes followed May layoffs totaling 40% of Lilly's sales force. In October, the company announced $5 billion worth of share buybacks to help pull shareholders through the difficulties still to come.
As far as making up for the sales hit from Zyprexa, Lilly is almost in the clear, according to Goldman Sachs analyst Jami Rubin. "Most of the year-over-year impact from the patent cliff will subside this quarter," she wrote in a note seen by Bloomberg. She also noted that large pharma companies aren't getting the credit they deserve for pipeline products. Assuming FDA approval, Lilly has four new diabetes drugs slated to hit the market in 2014 and 2015, Bloomberg reports.
Those could provide a needed boost for Lilly, whose stock has fallen more than 4% within the last year. Still, Rubin, for one, is not convinced Lilly can ride its diabetes franchise into the sunset, especially with rival drugs from fellow heavyweights Merck ($MRK), Pfizer ($PFE) and Johnson & Johnson ($JNJ) in the works. "Lilly has a clinical program heavy in diabetes where differentiation and reimbursement are likely to be challenging," she said.
___________________________________________________________
LLY
FDA Grants Lilly's Ramucirumab Priority Review For Advanced Gastric Cancer
By RTT News, October 23, 2013, 07:00:00 AM EDT
Eli Lilly and Co. ( LLY ) reported that the U.S. Food and Drug Administration or FDA has assigned Priority Review to the regulatory submission for ramucirumab as a single-agent treatment for advanced gastric cancer following disease progression after initial chemotherapy.
According to Richard Gaynor, M.D., vice president, product development and medical affairs for Lilly Oncology, "If approved, ramucirumab will be the first FDA-approved therapy for patients in this setting. Overall, stomach cancer is the second leading cause of cancer death globally and remains an area of high unmet need."
The Priority Review status for a biologics license application, or BLA, indicates that the FDA's aim is to take action within 8 months of a completed filing. Hence, Lilly expects agency action on this application in the second quarter of 2014. The priority designation aims at expediting the review of applications for drugs that, if approved, would represent a significant advance in treatment.
Also, Lilly studied ramucirumab in combination with paclitaxel for advanced gastric cancer treatment in its Phase III RAINBOW study. The combination-therapy ramucirumab data from that trial would be the basis for separate regulatory applications. Lilly sees top-line results from three additional Phase III trials of ramucirumab, one each in colorectal, hepatocellular (liver) and lung cancer, in 2014.
For comments and feedback: contact editorial@rttnews.com
http://www.rttnews.com
Read more: http://www.nasdaq.com/article/fda-grants-lillys-ramucirumab-priority-review-for-advanced-gastric-cancer-20131023-00226#ixzz2iXlHwrxr
________________________________________________________
LLY
Eli Lilly beats by $0.08, beats on revenues • 6:32 AM
Eli Lilly (LLY): Q3 EPS of $1.11 beats by $0.08.
Revenue of $5.77B (+6% Y/Y) beats by $0.01B. (PR)
LLY
Eli Lilly & Co. : Lilly Declares Fourth-Quarter 2013 Dividend
INDIANAPOLIS, Oct. 21, 2013 /PRNewswire/ --
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2013 of $0.49 per share on outstanding common stock.
The dividend is payable December 10, 2013 to shareholders of record at the close of business on November 15, 2013.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY
Refer to: (317) 276-5795 Mark Taylor
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
_____________________________________________________
http://www.4-traders.com/ELI-LILLY--CO-13401/news/Eli-Lilly--Co--Lilly-Declares-Fourth-Quarter-2013-Dividend-17382271/
LLY
10 top drugs in biopharma's late-stage pipeline
October 8, 2013
Let's start with the large print. In the past, when I assembled lists of the biggest blockbusters in the late-stage pipeline, I sometimes just looked for the largest peak sales estimates and went with them, including some extraordinarily high risk/high reward drugs where developers were simply rolling the dice on the outcome.
That explains how drugs like solanezumab and bapineuzumab appeared--even though I had little actual faith that they would turn in positive data. (They didn't.) Some bloggers went so far as to write about it, sagely noting their risks and wondering how many of those drugs would cross the finish line.
That was a mistake. Some analysts would put a peak sales number on fairy dust; or pump up the billions in the sales column to make a client look better. FiercePharma Editor Tracy Staton and I helped underscore that last fall with a roundup of 10 cautionary tales of blockbuster busts. And I find myself repeating that mantra now just about every day.
This year, I'm stepping back and recalibrating. Some drugs are far too speculative to include on any list of prospective game changers. Solanezumab, back in a new Phase III study, is on the lottery list. If Eli Lilly's ($LLY) continued willingness to invest vast sums of money working on a disease that remains a medical mystery eventually pays off, its revenue will outshine that of many if not all of the drugs you'll find below. So far, though, the pharma company has missed time and time again on Alzheimer's. Semagacestat, solanezumab, the decision to buy Amyvid--a diagnostic imaging agent that accomplishes … what?--helps make Lilly look quixotic, at best, which it insists against all appearances is not the case.
Eli Lilly, though, does make the grade here with dulaglutide, a diabetes medication that has some major league potential. I still have plenty of questions about safety and so on that could scuttle the program. Like many Big Pharma developers, Lilly is quite picky about what it will and will not talk about. And when its top execs do talk, reality often flies right out the window. But there's a case to be made here.
________________________________________________________________
Read more: 10 top drugs in biopharma's late-stage pipeline - FierceBiotech http://www.fiercebiotech.com/special-reports/10-top-drugs-biopharmas-late-stage-pipeline#ixzz2h9DQB6G3
Subscribe at FierceBiotech
LLY
Earnings in detail
project revenue to be between $22.6 billion and $23.4 billion
read here
http://www.earningsimpact.com/Transcript/82284/LLY/Q2-2013-Earnings-Call
I posted the CC highlights in #msg-89870017.
Business Update Call Updates
New pivotal trail for solanezumab called EXPEDITION 3
Transcript here
6:20 AM Eli Lilly (LLY) declares $0.49/share quarterly dividend, in line with previous. Forward yield 3.60%. For shareholders of record May 16. Payable June 10. Ex-div date May 14.
The uptrend is continuing since March 2009 and the stock has doubled in the last four years. The real upswing started in the middle of 2011. Even in the last year, the stock has moved up by around 40%. The sales and net income have not shown much growth over the last few years. In fact in 2012, the revenues were $22.60 billion compared with $24.86 billion in 2011 (decline of 9%). The net income has also fallen from $4.34 billion to $4.08 billion (a decline of 5.9%). LLY which is into discovery, development, manufacturing and selling of pharma products, has remained an excellent dividend payer. This is one attribute which makes it a preferred stock for investors (institutional ownership of 73%). All along, the dividends have been flowing at the rate of $1.96 per share per year. So the overall long term returns have been decent. The company is meeting revenue guidance (which has been low) but the drugs under development are not showing great promise. Success of pharma companies is heavily dependent on their ability to develop new drugs in segments which have good potential. One such potential segment on which LLY is concentrating is Oncology. The field is having a huge market and the company has a lot of stakes in it. Other smaller companies e.g. Senesco Technologies (SNTI) which are purely into research, have taken different approaches to treatment of different aspects of myeloma. LLY is one of the top ten cancer research firms in the world but its drugs have not been doing too well. Meanwhile the recent volumes have been low and the momentum is reducing. The fact that patents of some of its major drugs are likely to expire within the next few years will make it very difficult for it to sustain the sales even at current levels.
Good Story mentioning Eli Lilly...
http://emerginggrowth.com/emerging_growth_stock_picks/celldex-nasdaq-cldx-cutting-edge-products/01/16/2013
Many times investors make their stock choices based on how they climb in value on the market. However, savvy investors should also consider the companies that are setting the stage for a series of future significant milestones. Their cutting-edge products will be tapped by thousands of people, and the companies may make for future solid investment.
Let’s look at a company that must be given credit for its contributions to the pharmaceutical industry. Its emerging products will benefit many people affected by breast cancer. One of its treatment studies include CDX-011. The treatment is a conjugate that binds to a specific protein that promotes the migration, invasion, and metastasis of the disease. The company’s results demonstrate overall survival benefits.
CD-011 is the brainchild of Celldex Therapeutics (NASDAQ: CLDX). Since it announced the final results from its study, its stock has risen to $5 a share. While I think its great that Celldex is making progress with CD-011, that’s not the only thing that gets me excited by the stock. The breast cancer treatment is one in a line of studies carried out by the company. What piques my interest are the areas – outside breast cancer – that the company is studying. Another of its ongoing studies is on a vaccine that may act to promote anti-cancer effects in patients who have glioblastoma, a type of brain cancer.
“These events, coupled with ongoing activity in a number of other projects, will set the stage for a series of future milestones,” said Anthony Markucci, the CEO of Celldex while delivering the company’s third quarter report for the nine months ended September 30, 2012.
Celldex reported cash, cash equivalents, and marketing securities of $77.6 million, which the company believes will be sufficient to meet estimated working capital requirements and fund planned for program development into 2014. The decrease of $1.1 million from June 30, 2013 is due primarily to increased operational expenses during the quarter related to the vaccine on brain tumor. However, the cash outflows for these expenses were offset by the issuance of $2.0 million shares that raised net proceeds to Celldex of $10.9 million.
Sure, Celldex reported a net loss of $15 million for the third quarter of 2012 compared with a net loss of $11.8 million for the third quarter of 2011. It reported a net loss of $47.3 million for the nine months ended September 30, 2012, compared to a net loss of $32.1 million for the nine months ended September 30, 2011. But that is primarily due to increased operational expenses related to its studies.
Its competitors in the diagnostic substances industry are Dendreon Corp (NASDAQ: DNDN), Eli Lilly and Company (NYSE: LLY), and Roche Holding AG (NASDAQ: RHHBY). Trading at about $7.30 per share, its market cap is about $470 million. The decision as to whether to trade in Celldex in the first place rests with the individual trader. But if you want to place a pharmaceutical company on your watch list for 2013 and beyond, consider Celldex. Its emerging products may prove to be as strong as those produced by the world’s most valuable pharmaceutical companies.
4:50 PM Eli Lilly & Co. (LLY) declares $0.49/share quarterly dividend, in line with previous. Forward yield 4.05%. For shareholders of record Feb. 15. Payable Mar. 08. Ex-div date Feb. 13. The board approves share repurchase program of $1.5B.
http://seekingalpha.com/article/1000731-5-stocks-that-stand-to-benefit-from-unmet-need-for-alzheimer-s-disease?source=yahoo
Potential upside to LLY and other companies comparable other major pharma companies.
This diseases is a curse and could happen to any one once we hit a certain age.
10:52 AM Leerink Swan ups Eli Lilly (LLY +5.3%) to Outperform and raises sales estimates on the back of positive trial results for its gastric cancer treatment, ramucirumab. The firm thinks the recently released data shows encouraging potential for use on other tumor types, which could boost sales and lower the drug's overall marketing risk outlook.
4:20 PM Eli Lilly (LLY) declares $0.49/share quarterly dividend, in line with previous. Forward yield 3.89%. For shareholders of record Nov 15. Payable Dec 10. Ex-div date Nov 13
Lilly Announces Detailed Results of the Phase 3 Solanezumab EXPEDITION Studies Following a Presentation of the Independent An...
Lilly's analysis, as previously reported, showed primary endpoints, both cognitive and functional, were not met in the two Phase 3, double-blind, placebo-controlled solanezumab EXPEDITION trials in patients with mild-to-moderate Alzheimer's disease
In Lilly's pre-specified secondary analysis of pooled data in patients with mild Alzheimer's disease, a statistically significant slowing of cognitive decline was shown; this finding represented a 34 percent reduction in decline
Independent analyses of EXPEDITION studies conducted by the ADCS were generally similar to Lilly's top-line results reported on August 24, 2012
Next steps for solanezumab will be determined after discussions with regulators
Eli Lilly and Company (NYSE: LLY) today announced its detailed results for the Phase 3, double-blind, placebo-controlled EXPEDITION studies in patients with mild-to-moderate Alzheimer's disease. This announcement follows the presentation of results from independent analyses of the EXPEDITION study data conducted by the Alzheimer's Disease Cooperative Study (ADCS), an academic research consortium, at the annual meeting of the American Neurological Association (ANA) by Rachelle Doody, M.D., Ph.D., professor of Neurology and the Effie Marie Cain Chair in Alzheimer's Disease Research, Baylor College of Medicine. Dr. Doody is a member of the steering committee for the ADCS.
Lilly provided the raw data (the full data set collected from the EXPEDITION studies) to the ADCS. The ADCS statisticians then performed independent analyses of these data. These results were presented at today's meeting.
"Alzheimer's disease research has been extremely challenging," said Dr. Doody. "The data results from the solanezumab Phase 3 trials were encouraging to the ADCS team. These results represent an important step for the medical, academic, and scientific communities in understanding brain amyloid as a target of AD therapies."
Lilly's relationship with the ADCS is longstanding and the decision to have them conduct independent analyses of the Phase 3 solanezumab data was made prior to seeing the top-line results from either of the EXPEDITION studies.
Lilly Results from EXPEDITION1
The EXPEDITION1 study was designed with co-primary cognitive and functional endpoints (the Alzheimer's Disease Assessment Scale- Cognitive subscale [ADAS-Cog11] and the Alzheimer's Disease Cooperative Study-Activities of Daily Living [ADCS-ADL], respectively) in patients with mild-to-moderate Alzeimer's disease.
Lilly's pre-specified secondary analyses showed that results in patients with mild Alzheimer's disease taking solanezumab demonstrated a slowing of cognitive decline compared with placebo (p=.008), as measured by the ADAS- Cog11. This finding represented a 42 percent reduction in decline at the endpoint of the 18-month study. The difference in functional decline (ADCS-ADL) was not statistically significant.
Lilly Results from EXPEDITION2
Based on the results of EXPEDITION1, Lilly modified the statistical analysis plan (SAP) for EXPEDITION2, prior to database lock, to specify a single primary endpoint of cognition in patients with mild Alzheimer's disease as measured by the ADAS-Cog14, a 14-item scale, which includes three additional items considered relevant for patients with mild Alzheimer's disease.1 At the conclusion of EXPEDITION2, there was a 20 percent reduction in cognitive decline in patients with mild Alzheimer's disease taking solanezumab; however, the treatment difference was not statistically significant (p=.120). In the pre-specified secondary endpoint of ADCS-ADL, there was a 19 percent reduction in functional decline in patients with mild Alzheimer's disease treated with solanezumab, as compared with placebo; this difference was not statistically significant (p=.076).
Lilly Results from Pooled Analyses of EXPEDITION1 and EXPEDITION2
A pre-specified secondary analysis of pooled data in patients with mild Alzheimer's disease showed a slowing of cognitive decline (p=.001) compared with placebo, as measured by the ADAS-Cog14; this finding represented a 34 percent reduction in decline. In addition, the secondary analysis of the pooled data in patients with mild Alzheimer's disease showed a 17 percent reduction of functional decline as measured by the ADCS-ADL; however, the treatment difference was not statistically significant compared with placebo (p=.057).
A number of different biomarkers were assessed in the EXPEDITION studies. Some, but not all, of these biomarkers showed an effect of solanezumab. These additional data will be presented by the ADCS at the Clinical Trials on Alzheimer's Disease (CTAD) meeting in Monte Carlo, Monaco, on October 29, 2012, or at subsequent medical meetings and in appropriate scientific venues.
In the EXPEDITION studies, the only adverse event with an incidence of at least 1 percent that occurred statistically significantly more in the solanezumab group than in the placebo group was angina (1.1 percent versus 0.2 percent). The incidence of vasogenic edema (ARIA-E) was approximately 1 percent, occurring in 11 patients treated with solanezumab and 5 patients on placebo, which was not statistically significant.
"This is a complex disease that touches millions of people worldwide," said David Ricks, senior vice president and president, Lilly Bio-Medicines. "Alzheimer's disease causes significant burden on patients, caregivers and our society. While the path forward has not been determined, we believe these data in patients with mild disease may provide a step toward a potential treatment option."
About the Primary Endpoint Scales2
The ADAS-Cog is a standard tool used in pivotal clinical trials to detect therapeutic efficacy in cognition. It consists of subtests related to memory, praxis, and language. Higher scores on the ADAS-Cog indicate more cognitive impairment. The ADCS-ADL measures activities of daily living, such as reading books or magazines, pastime activities, or household chores. Higher scores on the ADCS-ADL indicate less functional impairment.
About the EXPEDITION Trials
The EXPEDITION trials consisted of two Phase 3, double-blind, placebo-controlled solanezumab trials in patients with mild-to-moderate Alzheimer's disease in 16 countries around the world. In both of the EXPEDITION study protocols, mild Alzheimer's disease was defined as a baseline Mini-Mental Status Examination (MMSE) score of 20 to 26 and moderate Alzheimer's disease was defined as a baseline MMSE score of 16 to 19.
The designs of EXPEDITION1 and EXPEDITION2 were the same. Patients aged 55-94 years were eligible to enroll in these studies; EXPEDITION1 enrolled 1,012 patients and EXPEDITION2 enrolled 1,040 patients. Patients received either 400mg of solanezumab infused intravenously (IV) or placebo every four weeks for approximately 18 months. Both EXPEDITION trials allowed patients to remain on stable standard of care (defined as their existing treatment regimen) during these studies. More than 85 percent of the patients in these trials were taking an acetycholinesterase inhibitor and / or memantine.
About Alzheimer's disease
Alzheimer's disease, the most common form of dementia, causes progressive decline in memory and other aspects of cognition.3,4 Researchers do not know exactly what causes Alzheimer's disease and there are currently no approved treatments shown to slow the progression of this devastating disease, only treatment options that reduce certain symptoms of the disease.2,3,5 Alzheimer's Disease International (ADI) estimates that there are currently 35.6 million people with dementia worldwide, with 7.7 million new cases each year (which implies one new case every four seconds).6 The number of people affected is estimated to be over 115 million by 2050.4 Estimates vary, but experts suggest that as many as 5.4 million Americans may have Alzheimer's disease.3
About Eli Lilly and Company
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. P-LLY
This press release contains certain forward-looking statements about solanezumab. This release reflects Lilly's current beliefs; however, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that future study results and patient experience will be consistent with study findings to date, or that solanezumab will be approved as a product or will prove to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.
1 Mohs R, Knopman D, Petersen RC, Ferris SH, Ernesto C, Grundman M, Sano M, Bieliauskas L, Geldmacher D, Clark C, Thal LJ, and the Alzheimer's Disease Cooperative Study. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broadens its scope. Alzheimer Dis Assoc Disord 1997;11(Suppl 2):S13-S21. 2 Robert P, Ferris S, Gauthier S, Ihl R, Winblad B, Tennigkeit F. Review of Alzheimer's disease Scales: Is There a Need for a New Multi-domain Scale for Therapy Evaluation in Medical Practice?. Alzheimer's Research & Therapy. 2010; 2(24): 1-13.3 National Institute of Neurological Disorders and Stroke. "Dementia: Hope Through Research." Available at: http://www.ninds.nih.gov/disorders/dementias/detail_dementia.htm#1908919213. Accessed on August 13, 2012. 4 Alzheimer's Association. "2012 Alzheimer's Disease Facts and Figures." Available at: http://www.alz.org/downloads/facts_figures_2012.pdf. Accessed on August 13, 2012. 5 Perrin, R., et al. "Multimodal techniques for diagnosis and prognosis of Alzheimer's disease." Nature 2009 (461); 916-922. 6 Alzheimer's Disease International. "Dementia Statistics." Available at: http://www.alz.co.uk/research/statistics. Accessed on August 13, 2012.
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
7:41 AM On the back of positive results for its Alzheimer's treatment, Eli Lilly (LLY) is upgraded to Neutral with $54 price target from Sell and $42 at Goldman. "Our skepticism was proven wrong." Shares +1% premarket.
1:59 PM Eli Lilly (LLY +2.6%) pops after a new study shows its experimental Alzheimer’s treatment slowed memory loss and cognitive decline in early-stage patients by ~30%, offering the first evidence that a medication may hamper the course of the ailment. The independent analysis supports LLY’s August report that showed the drug, solanezumab, slowed mental decline in those with mild Alzheimer’s
It's a extension into 1st line combined with folfiri. Kras testing is needed.
I would think it has been being used in that indication so I wouldn't expect any sales appreciation per se.
Is this really an expansion? It sounds instead like a refinement of the Erbitux label.
Bristol-Myers Squibb Co. (BMY) and Eli Lilly & Co. (LLY) won U.S. regulatory approval to expand the use of Erbitux as an initial treatment against colorectal cancer that has spread for patients who are first given a genetic screening.
Erbitux should be taken only by patients who have used an agency-approved test to predict whether the drug will work, according to the medicine’s label posted on the Food and Drug Administration’s website. The agency also cleared the threascreen test made by Venlo, Netherlands-based Qiagen NV (QGEN), the first FDA-approved diagnostic that will evaluate each patient’s likelihood of responding to the cancer treatment, Michelle Bolek, a spokeswoman for the agency, said in an e-mail.
Erbitux fails phase-3 trial in stomach cancer; prospects in NSCLC considered dim:
#msg-77240378.
Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
Lilly Eli (NYSE:LLY)
Today : Tuesday 19 June 2012
Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
INDIANAPOLIS, June 19, 2012 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the third quarter of 2012 of $0.49 a share on outstanding common stock. The dividend is payable September 10, 2012 to shareholders of record at the close of business on August 15, 2012.
The Lilly board of directors has also authorized the resumption of a share repurchase program that was started in 2000, under which the company has thus far purchased $2.58 billion of shares of a total authorization of $3.0 billion. The company expects to complete this program by purchasing the remaining $420 million in shares by the end of 2012. The company also anticipates resuming systematic share repurchases following the completion of the current program. The size and timing of these additional share repurchases will be subject to board approval and will be balanced with other cash flow considerations, including the funding of the company's dividend, capital expenditures, potential business development opportunities and worldwide macroeconomic conditions.
"At Lilly, we're committed to providing a positive return to our shareholders through both a healthy dividend and stock price appreciation. Based on current market valuations and our confidence in Lilly's future, we believe that now is an excellent opportunity to resume buying back Lilly shares even as we maintain the dividend at least at its current level," said John Lechleiter, Ph.D., Lilly chairman, president, and chief executive officer.
All purchases under the share repurchase program will be made on the open market at prevailing prices. Purchases will be made over a period to be determined by management of the company. Shares acquired will be retired. As of March 31, 2012 there were 1,116,982,662 shares of stock outstanding on a diluted basis.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY
This press release contains forward-looking statements that are based on management's current expectations, but actual results may differ materially due to various factors. There is no guarantee the company will be able to complete its planned 2012 share repurchases or will continue repurchasing shares in 2013 or beyond. There are significant risks and uncertainties in pharmaceutical research and development. There can be no guarantees with respect to pipeline products that the products will receive the necessary clinical and manufacturing regulatory approvals or that they will prove to be commercially successful. Pharmaceutical products can develop unexpected safety or efficacy concerns. The company's results may also be affected by such factors as competitive developments affecting current products; market uptake of recently launched products; the timing of anticipated regulatory approvals and launches of new products; regulatory actions regarding currently marketed products; issues with product supply; regulatory changes or other developments; regulatory compliance problems or government investigations; patent disputes; changes in patent law or regulations related to data-package exclusivity; other litigation involving current or future products; the impact of governmental actions regarding pricing, importation, and reimbursement for pharmaceuticals, including U.S. health care reform; changes in tax law; asset impairments and restructuring charges; acquisitions and business development transactions; and the impact of exchange rates and global macroeconomic conditions. For additional information about the factors that affect the company's business, please see the company's latest Form 10-Q and Form 10-K filed with the U.S. Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements.
8:29 AM Eli Lilly (LLY +0.6%) declares a Q3 dividend of $0.49 a share and says it will repurchase $420M in stock by the end of 2012 as part of the resumption of a $3B stock buyback program. It's been a long buyback - it started in 2000. The company hopes to begin a new program after it completes the current one.
Lilly Reports Solid Start to the Year With First-Quarter 2012 Results, Raises EPS Guidance
Date : 04/25/2012 @ 6:30AM
Source : PR Newswire
Stock : Lilly Eli (LLY)
~ Wednesday! $LLY ~ Q1 Earnings posted, pending or coming soon! In Charts and Links Below!
~ $LLY ~ Earnings expected on Wednesday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=LLY&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=LLY&p=W&b=3&g=0&id=p54550695994
~ Google Finance: http://www.google.com/finance?q=LLY
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=LLY#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=LLY+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=LLY
Finviz: http://finviz.com/quote.ashx?t=LLY
~ BusyStock: http://busystock.com/i.php?s=LLY&v=2
<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=LLY >>>>>>
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
<<< $LLY Links! >>> ~ MAC's Quick DD Links without the charts.
PennyStockTweets ~ http://www.pennystocktweets.com/stocks/profile/LLY
OTC Markets Company Info ~ http://www.otcmarkets.com/stock/LLY/company-info
OTC Markets Charts ~ http://www.otcmarkets.com/stock/LLY/chart
OTC Markets Quote ~ http://www.otcmarkets.com/stock/LLY/quote
OTC Markets News ~ http://www.otcmarkets.com/stock/LLY/news
OTC Markets Financials ~ http://www.otcmarkets.com/stock/LLY/financials
OTC Markets Short Sales ~ http://www.otcmarkets.com/stock/LLY/short-sales
OTC Markets Insider Disclosure ~ http://www.otcmarkets.com/stock/LLY/insider-transactions
OTC Markets Research Reports ~ http://www.otcmarkets.com/stock/LLY/research
Google Finance Summary ~ http://www.google.com/finance?q=LLY
Google Finance News ~ http://www.google.com/finance/company_news?q=LLY
Google Finance Option chain ~ http://www.google.com/finance/option_chain?q=LLY
Google Finance Financials ~ http://www.google.com/finance?q=LLY&fstype=ii#
Google Finance Historical prices Daily ~ http://www.google.com/finance/historical?q=LLY
Google Finance Historical prices Weekly ~ http://www.google.com/finance/historical?q=LLY&histperiod=weekly#
Y! < Company >
Y! Profile ~ http://finance.yahoo.com/q/pr?s=LLY+Profile
Y! Key Stat's ~ http://finance.yahoo.com/q/ks?s=LLY+Key+Statistics
Y! Headlines ~ http://finance.yahoo.com/q/h?s=LLY+Headlines
Y! Summary ~ http://finance.yahoo.com/q?s=LLY
Y! Historical Prices ~ http://finance.yahoo.com/q/hp?s=LLY+Historical+Prices
Y! Order Book ~ http://finance.yahoo.com/q/ecn?s=LLY+Order+Book
Y! Message Boards ~ http://messages.finance.yahoo.com/mb/LLY
Y! Market Pulse ~ http://finance.yahoo.com/marketpulse/LLY
Y! Technical Analysis ~ http://finance.yahoo.com/q/ta?s=LLY+Basic+Tech.+Analysis
Y! < Analyst Coverage >
Y! Analyst Opinion ~ http://finance.yahoo.com/q/ao?s=LLY+Analyst+Opinion
Y! Analyst Estimates ~ http://finance.yahoo.com/q/ae?s=LLY+Analyst+Estimates
Y! Research Reports ~ http://finance.yahoo.com/q/rr?s=LLY+Research+Reports
Y! Star Analysts ~ http://finance.yahoo.com/q/sa?s=LLY+Star+Analysts
Y! < Ownership >
Y! Major Holders ~ http://finance.yahoo.com/q/mh?s=LLY+Major+Holders
Y! Insider Transactions ~ http://finance.yahoo.com/q/it?s=LLY+Insider+Transactions
Y! Insider Roster ~ http://finance.yahoo.com/q/ir?s=LLY+Insider+Roster
Y! < Financials >
Y! Income Statement ~ http://finance.yahoo.com/q/is?s=LLY+Income+Statement&annual
Y! Balance Sheet ~ http://finance.yahoo.com/q/bs?s=LLY+Balance+Sheet&annual
Y! Cash Flow ~ http://finance.yahoo.com/q/cf?s=LLY+Cash+Flow&annual
FINVIZ ~ http://finviz.com/quote.ashx?t=LLY&ty=c&ta=0&p=d
Investorshub Trades ~ http://ih.advfn.com/p.php?pid=trades&symbol=LLY
Investorshub Board Search ~ http://investorshub.advfn.com/boards/getboards.aspx?searchstr=LLY
Investorshub PostStream ~ http://investorshub.advfn.com/boards/poststream.aspx?ticker=LLY
Investorshub Messages ~ http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=LLY
Investorshub Videos ~ http://ih.advfn.com/p.php?pid=ihvse&ihvqu=LLY
Investorshub News ~ http://ih.advfn.com/p.php?pid=news&btn=s_ok&ctl00%24sb3%24tbq1=Get+Quote&as_values_IH=&ctl00%24sb3%24stb1=Search+iHub&symbol=LLY&s_ok=OK&from_month=3&from_day=15&from_year=2012&order=desc&selsrc%5B%5D=prnca&selsrc%5B%5D=prnus&selsrc%5B%5D=zacks&selsrc%5B%5D=money2&selsrc%5B%5D=djn&selsrc%5B%5D=bw&selsrc%5B%5D=globe&selsrc%5B%5D=edgar&selsrc%5B%5D=mwus&force=1&last_ts=1331855999&p_n=1&p_count=&p_ts=1331794260
CandlestickChart ~ http://www.candlestickchart.com/cgi/chart.cgi?symbol=LLY&exchange=US
Barchart Quote ~ http://barchart.com/quotes/stocks/LLY?
Barchart Detailed Quote ~ http://barchart.com/detailedquote/stocks/LLY
Barchart Options Quotes ~ http://barchart.com/options/stocks/LLY
Barchart Technical Chart ~ http://barchart.com/charts/stocks/LLY&style=technical
Barchart Interactive Chart ~ http://barchart.com/charts/stocks/LLY&style=interactive
Barchart Technical Analysis ~ http://barchart.com/technicals/stocks/LLY
Barchart Trader's Cheat Sheet ~ http://barchart.com/cheatsheet.php?sym=LLY
Barchart Barchart Opinion ~ http://barchart.com/opinions/stocks/LLY
Barchart Snapshot Opinion ~ http://barchart.com/snapopinion/stocks/LLY
Barchart News Headlines ~ http://barchart.com/news/stocks/LLY
Barchart Profile ~ http://barchart.com/profile//LLY
Barchart Key Statistics ~ http://barchart.com/profile.php?sym=LLY&view=key_statistics
OTC: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=LLY&MarketTicker=OTC&TYP=S
NASDAQ: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=LLY&MarketTicker=NASD&TYP=S
NYSE: American Bulls ~ http://www.americanbulls.com/StockPage.asp?CompanyTicker=LLY&MarketTicker=NYSE&Typ=S
Marketwatch Profile ~ http://www.marketwatch.com/investing/stock/LLY/profile
Marketwatch Analyst Estimates ~ http://www.marketwatch.com/investing/stock/LLY/analystestimates
Marketwatch Historical Quotes ~ http://www.marketwatch.com/investing/stock/LLY/historical
Marketwatch Financials ~ http://www.marketwatch.com/investing/stock/LLY/financials
Marketwatch Overview ~ http://www.marketwatch.com/investing/stock/LLY
Marketwatch SEC Filings ~ http://www.marketwatch.com/investing/stock/LLY/secfilings
Marketwatch Picks ~ http://www.marketwatch.com/investing/stock/LLY/picks
Marketwatch Hulbert ~ http://www.marketwatch.com/investing/stock/LLY/hulbert
Marketwatch Insider Actions ~ http://www.marketwatch.com/investing/stock/LLY/insideractions
Marketwatch Options ~ http://www.marketwatch.com/investing/stock/LLY/options
Marketwatch Charts ~ http://www.marketwatch.com/investing/stock/LLY/charts
Marketwatch News ~ http://bigcharts.marketwatch.com/news/symbolsearch/symbolnews.asp?news=markadv&symb=LLY&sid=1795093&framed=False
The Lion ~ http://thelion.com/bin/aio_msg.cgi?cmd=search&msg=&si=1&tw=1&tt=1&rb=1&ih=1&fo=1&iv=1&yf=1&sa=1&fb=1&gg=1&symbol=LLY
Search NYSE ~ http://www.nyse.com/about/listed/lcddata.html?ticker=LLY
StockTA ~ http://www.stockta.com/cgi-bin/analysis.pl?symb=LLY&num1=567&cobrand=&mode=stock
StockHouse ~ http://www.stockhouse.com/financialtools/sn_overview.aspx?qm_symbol=LLY
StockHouse Delayed LII ~ http://www.stockhouse.com/financialtools/sn_level2.aspx?qm_page=46140&qm_symbol=LLY
AlphaTrade ~ http://tools.alphatrade.com/index.php?t1=mc_quote_module&t2=mc_quote_module2&t3=historical&template=historical2html&sym=LLY&client_id=2740&a_width=680&a_height=1000&language=english&showVol=1&chtype=8
Reuters ~ http://www.reuters.com/finance/stocks/companyOfficers?symbol=LLY.PK&WTmodLOC=C4-Officers-5
StockWatch ~ http://www.stockwatch.com/Quote/Detail.aspx?symbol=LLY®ion=U
Search NASDAQ ~ http://www.nasdaq.com/symbol/LLY
NASDAQ Divy History ~ http://www.nasdaq.com/symbol/LLY/dividend-history
NASDAQ Short Interest ~ http://www.nasdaq.com/symbol/LLY/short-interest
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/LLY/institutional-holdings
NASDAQ FlashQuotes ~ http://www.nasdaq.com/aspx/flashquotes.aspx?symbol=LLY&selected=LLY
NASDAQ InfoQuotes ~ http://www.nasdaq.com/aspx/infoquotes.aspx?symbol=LLY&selected=LLY
NASDAQ After Hours Quote ~ http://www.nasdaq.com/symbol/LLY/after-hours
NASDAQ Pre-Market Quote ~ http://www.nasdaq.com/symbol/LLY/premarket
NASDAQ Historical Quote ~ http://www.nasdaq.com/symbol/LLY/historical
NASDAQ Option Chain ~ http://www.nasdaq.com/symbol/LLY/option-chain
NASDAQ Company Headlines ~ http://www.nasdaq.com/symbol/LLY/news-headlines
NASDAQ Press Releases ~ http://www.nasdaq.com/symbol/LLY/news-headlines
NASDAQ Sentiment ~ http://www.nasdaq.com/symbol/LLY/sentiment
NASDAQ Analyst Summary ~ http://www.nasdaq.com/symbol/LLY/analyst-research
NASDAQ Guru Analysis~ http://www.nasdaq.com/symbol/LLY/guru-analysis
NASDAQ Stock Report ~ http://www.nasdaq.com/symbol/LLY/stock-report
NASDAQ Competitors ~ http://www.nasdaq.com/symbol/LLY/competitors
NASDAQ Stock Consultant ~ http://www.nasdaq.com/symbol/LLY/stock-consultant
NASDAQ Stock Comparison ~ http://www.nasdaq.com/symbol/LLY/stock-comparison
NASDAQ Call Transcripts ~ http://www.nasdaq.com/symbol/LLY/call-transcripts
NASDAQ Annual Reports ~ http://www.nasdaq.com/aspx/annualreport.aspx?symbol=LLY&selected=LLY
NASDAQ Financials ~ http://www.nasdaq.com/symbol/LLY/financials
NASDAQ Revenue & Earnings Per Share (EPS) ~ http://www.nasdaq.com/symbol/LLY/revenue-eps
NASDAQ SEC Filings ~ http://www.nasdaq.com/symbol/LLY/sec-filings
NASDAQ Ownership Summary ~ http://www.nasdaq.com/symbol/LLY/ownership-summary
NASDAQ Institutional Ownership ~ http://www.nasdaq.com/symbol/LLY/institutional-holdings
NASDAQ (SEC Form 4) ~
--------- All Trades ~ http://www.nasdaq.com/symbol/LLY/insider-trades
--------- Buys ~ http://www.nasdaq.com/symbol/LLY/insider-trades/buys
--------- Sells ~ http://www.nasdaq.com/symbol/LLY/insider-trades/sells
The Motley Fool ~ http://caps.fool.com/Ticker/LLY.aspx
The Motley Fool Earnings/Growth ~ http://caps.fool.com/Ticker/LLY/EarningsGrowthRates.aspx?source=itxsittst0000001
The Motley Fool Ratios ~ http://caps.fool.com/Ticker/LLY/Ratios.aspx?source=itxsittst0000001
The Motley Fool Stats ~ http://caps.fool.com/Ticker/LLY/Stats.aspx?source=icasittab0000006
The Motley Fool Historical ~ http://caps.fool.com/Ticker/LLY/Historical.aspx?source=icasittab0000004
The Motley Fool Scorecard ~ http://caps.fool.com/Ticker/LLY/Scorecard.aspx?source=icasittab0000003
The Motley Fool Statements ~ http://caps.fool.com/Ticker/LLY/Statements.aspx?source=icasittab0000009
MSN Money ~ http://investing.money.msn.com/investments/stock-ratings?symbol=LLY
YCharts ~ http://ycharts.com/companies/LLY
YCharts Performance ~ http://ycharts.com/companies/LLY/performance
YCharts Dashboard ~ http://ycharts.com/companies/LLY/dashboard
InsideStocks Opinion ~ http://www.insidestocks.com/texpert.asp?sym=LLY&code=XDAILY
InsideStocks Profile ~ http://www.insidestocks.com/profile.asp?sym=LLY&code=XDAILY
InsideStocks Quote ~ http://www.insidestocks.com/quote.asp?sym=LLY&code=XDAILY
InsideStocks Projection ~ http://charts3.barchart.com/procal.asp?sym=LLY
Zacks Quote ~ http://www.zacks.com/stock/quote/LLY
Zacks Estimates ~ http://www.zacks.com/research/report.php?type=estimates&t=LLY
Zacks Company Reports ~ http://www.zacks.com/research/report.php?type=report&t=LLY
Knobias ~ http://knobias.10kwizard.com/files.php?sym=LLY
StockScores ~ http://www.stockscores.com/quickreport.asp?ticker=LLY
Trade-Ideas ~ http://www.trade-ideas.com/StockInfo/LLY/HOT_TOPIC.html
Morningstar ~ http://performance.morningstar.com/stock/performance-return.action?region=USA&t=LLY&culture=en-US
Morningstar Shareholders ~ http://investors.morningstar.com/ownership/shareholders-overview.html?t=LLY®ion=USA&culture=en-us
Morningstar Transcripts~ http://www.morningstar.com/earnings/NoTranscript.aspx?t=LLY®ion=USA
Morningstar Key Ratios ~ http://financials.morningstar.com/ratios/r.html?t=LLY®ion=USA&culture=en-US
Morningstar Executive Compensation ~ http://insiders.morningstar.com/trading/executive-compensation.action?t=LLY®ion=USA&culture=en-us
Morningstar Valuation ~ http://financials.morningstar.com/valuation/price-ratio.html?t=LLY®ion=USA&culture=en-us
CCBN (Thompson Reuters) ~ http://ccbn.aol.com/company.asp?client=aol&ticker=LLY
TradingMarkets ~ http://pr.tradingmarkets.com/?lid=leftPRbox&sym=LLY
OTCBB ~ http://www.otcbb.com/asp/SiteSearch.asp?Criteria=LLY&searcharea=e&image1.x=0&image1.y=0
Insidercow ~ http://www.insidercow.com/history/company.jsp?company=LLY&B1=Search%21
Forbes News ~ http://search.forbes.com/search/find?tab=searchtabgeneraldark&MT=LLY
Forbes Press Releases ~ http://search.forbes.com/search/find?&start=1&tab=searchtabgeneraldark&MT=LLY&pub=businesswire,prnewswire&searchResults=pressRelease&tag=pr&premium=on
Forbes Web ~ http://search.forbes.com/search/web?MT=UNGS&start=1&max=10&searchResults=web&tag=web&sort=null
YouTube Symbol Search ~ http://www.youtube.com/results?search_query=LLY
Buy-Ins ~ http://www.buyins.net/tools/symbol_stats.php?sym=LLY
Quotemedia ~ http://www.quotemedia.com/results.php?qm_page=47556&qm_symbol=LLY
Earnings Whispers ~ http://www.earningswhispers.com/stocks.asp?symbol=LLY
Bloomberg Snapshot ~ http://investing.businessweek.com/research/stocks/snapshot/snapshot.asp?ticker=LLY
Bloomberg People ~ http://investing.businessweek.com/research/stocks/people/people.asp?ticker=LLY
Financial Times ~ http://markets.ft.com/Research/Markets/Tearsheets/Summary?s=LLY
Investorpoint ~ http://www.investorpoint.com/ enter "LLY" and click search.
Hotstocked ~ http://www.hotstocked.com/ enter "LLY" and click search.
Raging Bull ~ http://ragingbull.quote.com/mboard/boards.cgi?board=LLY
Hoovers ~ http://www.hoovers.com/search/company-search-results/100003765-1.html?type=company&term=LLY
DD Machine ~ http://www.ddmachine.com/default.asp?m=stocktool_frame.asp?symbol=LLY
SEC Form 4 ~ http://www.secform4.com/insider/showhistory.php?cik=LLY
OTCBB Pulse ~ http://www.otcbbpulse.com/cgi-bin/pulsequote.cgi?symbol=LLY
Failures To Deliver ~ http://failurestodeliver.com/default2.aspx enter "LLY" and click search.
http://www.coordinatedlegal.com/SecretaryOfState.html
http://regsho.finra.org/regsho-Index.html
http://www.shortsqueeze.com/?symbol=LLY&submit=Short+Quote%99
DTCC (PENSON/TDA) Check - (otc and pinks) - Note ~ I did not check for this chart blast. However, I try and help you to do so with the following links.
IHUB DTCC BOARD SEARCH #1 http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=LLY
IHUB DTCC BOARD SEARCH #2: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=14482&srchyr=2011&SearchStr=LLY
Check those searches for recent LLY mentions. If LLY is showing up on older posts and not on new posts found in link below, The DTCC issues may have been addressed and fixed. Always call the broker if your security turns up on any DTCC/PENSON list.
http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18682&srchyr=2011&SearchStr=Complete+list
For a complete list see the pinned threads at the top here ---> http://tinyurl.com/TWO-OLD-FARTS
MACDlinks
Lilly Confirms Date and Conference Call for First-Quarter 2012 Financial Results Announcement
Lilly Eli (NYSE:LLY)
Today : Thursday 12 April 2012
Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2012 on Wednesday, April 25, 2012. Lilly will also conduct a conference call on that day with the investment community and media to further detail the company's financial performance.
The conference call will be held from 9:00 a.m. to 10:00 a.m. EDT. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at www.lilly.com. A replay will also be available on the website following the conference call.
Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com. F-LLY
(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO )
SOURCE Eli Lilly and Company
1:58 PM Eli Lilly (LLY -0.1%) hopes that a new radioactive dye used to detect Alzheimer's disease will kick up enough revenue to make up for lost income from two patents on high-selling drugs set to expire. CEO Jon Lechleiter tells CNBC (video) the company is working with Medicare and other constituents to get reimbursement coverage for patients undergoing using the brain test with its dye
12:13 PM Eli Lilly (LLY -0.7%) plans to introduce over a dozen different products in China over the next five years in order to achieve a stated goal of being the fastest-growing pharma name in the nation. One area in particular targeted by the company will be the diabetes treatment market - expected to grow to $2.1B by 2019.
~ $LLY ~ Earnings posted, pending or coming soon! In Charts and Links Below!
~ $LLY ~ Earnings expected on Tuesday *
This Week In Earnings: Earnings are coming or are already posted! This is what the charts look like! If you play the earnings these posts can be very helpful to you!
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.
http://stockcharts.com/h-sc/ui?s=LLY&p=D&b=3&g=0&id=p88783918276&a=237480049
http://stockcharts.com/h-sc/ui?s=LLY&p=W&b=3&g=0&id=p54550695994
~ Barchart: http://barchart.com/quotes/stocks/LLY?
~ OTC Markets: http://www.otcmarkets.com/stock/LLY/company-info
~ Google Finance: http://www.google.com/finance?q=LLY
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=LLY#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=LLY+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=LLY
Finviz: http://finviz.com/quote.ashx?t=LLY
~ BusyStock: http://busystock.com/i.php?s=LLY&v=2
~ CandlestickChart: http://www.candlestickchart.com/cgi/chart.cgi?symbol=LLY&exchange=US
~ Investorshub Trades: http://ih.advfn.com/p.php?pid=trades&symbol=LLY
~ Investorshub Board Search: http://investorshub.advfn.com/boards/getboards.aspx?searchstr=LLY
~ Investorshub PostStream Search: http://investorshub.advfn.com/boards/poststream.aspx?ticker=LLY
~ Investorshub Goodies Search: http://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardID=18582&srchyr=2011&SearchStr=LLY
~ Investorshub Message Search: http://investorshub.advfn.com/boards/msgsearch.aspx?SearchStr=LLY
~ MarketWatch: http://www.marketwatch.com/investing/stock/LLY/profile
~ E-Zone Chart: http://www.windchart.com/ezone/signals/?symbol=LLY
~ 5-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LLY
~ 10-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LLY&size=l&frequency=10&color=g
~ 30-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LLY&size=l&frequency=30&color=g
~ 60-Min Wind: http://www.windchart.com/stockta/analysis?symbol=LLY&size=l&frequency=60&color=g
http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916
*If the earnings date is in error please ignore error. I do my best.
LLY’s Evacetrapib boosts good cholesterol: #msg-69029766.
Followers
|
37
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
170
|
Created
|
04/07/08
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |